CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
MAC30 has recently opened in Canada and will compare two commonly used treatment choices for premenopausal women with ER-positive/HER2-negative breast cancer and a low to intermediate risk of recurrence. Researchers are testing the addition of chemotherapy to ovarian function suppression plus hormonal therapy versus ovarian function suppression plus hormonal therapy alone. Both these approaches are used across North America, and it is not clear as to whether chemotherapy is needed in this population.
The IND.227: A Phase II/III Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma has permanently trial closed.
October is breast cancer awareness month and in recognition we have a new video interview with our CCTG Breast Cancer Patient Representative Michelle Audoin.
"The research investments in cancer clinical trials and progressive treatment options I have seen in recent years give me hope for the future. Which is why it’s important for me to bring my voice to the development of cancer clinical trials. I want to support inclusive trial enrollment, thereby improving the generalizability of results for diverse communities," says Michelle.
Joseph L. Pater, O.C. Kingston, Ontario
MAC23 (Oral, Plenary) - https://www.redjournal.org/article/S0360-3016(24)00764-8/fulltext
A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)
The CCTG HN10 (EVADER) results were presented at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting in Washington DC. The late breaking results concluded that radiotherapy to some of the lymph node areas can be safely excluded to decrease side effects without compromising tumour control.
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
The HE1 clinical trial has permanently closed, the study confirmed that the quality-of-life benefits of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases. This trial no longer requires action, including the cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals.
Primary Publication
